Table 2.
Most significant single SNP associations with ≥grade 3 neuropathy in meta-analyses of S0221 and CALGB40101
| Chr:SNP | Alleles Ɛ |
Geneβ | bp (hg19) | S0221 European Americans (147 ≥grade 3, 1122 < grade 3) |
S0221 African Americans (31 ≥grade 3, 108 <grade 3) |
CALGB40101 European Americans (57 ≥grade 3, 797<grade 3) |
Meta-analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EAF |
Pƈ | OR (95% CI) |
EAF | Pƈ | OR (95% CI) |
EAF | P | OR (95% CI) |
EAF ≥3 grade/ grade <3 |
OR (95% CI) |
P | ||||
| 7:rs1858826 | A/G | GNGT1 | 93349015 | .09 | 8.2 × 10−7 | .21 (.10, .46) | 0.12 | .04 | 0.26 (.07, .95) | .10 | .07 | .47 (.20, 1.09) | .03/.10 | .29 (.18, .46) | 1.1×10−7 |
| 17:rs910920 | A/G | NXN | 701122 | .29 | 1.3 × 10−7 | 0.44 (.32, .61) | 0.26 | 0.81 | 0.91 (.45, 1.87) | .28 | .20 | .73 (.49, 1.1) | .22/.31 | .57 (.45, .73) | 4.9×10−6 |
| 4:rs1857798 | C/T | MIR5684 | 165370126 | .35 | .01 | 0.73 (.56, .95) | 0.16 | .04 | .33 (.11, .99) | .37 | 5 × 10−4 | .44 (.28, .69) | .30/.38 | 0.44 (.29,.66) | 8.3×10−6 |
| 6:rs12202642 | C/T | FGD2 | 36979583 | .05 | .02 | 2.98 (1.6, 5.4) | 0.12 | .04 | 13.7 (1.06, 175.7) | .05 | 4 × 10−4 | 2.01 (1.1, 3.8) | .06/.03 | 3.0 (1.7, 5.3) | 1.2×10−5 |
Ɛ
=Effect allele is bolded;
β
=the closet flanking annotated gene is noted if SNP is intergenic.;
EAF=effect allele frequency;
ƈ
=likelihood ratio test p-values